We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Use of Cell-free DNA Liquid Biopsy to Predict Glioblastoma Progression

By LabMedica International staff writers
Posted on 11 Nov 2019
Print article
Image: A liquid biopsy blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream correlates with how patients will progress after they are diagnosed with glioblastoma (Photo courtesy of University of Pennsylvania School of Medicine).
Image: A liquid biopsy blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream correlates with how patients will progress after they are diagnosed with glioblastoma (Photo courtesy of University of Pennsylvania School of Medicine).
Cancer researchers have demonstrated the potential clinical utility of liquid biopsy to measure plasma cell-free DNA (cfDNA) in patients with newly diagnosed glioblastoma in order to predict the progression of the disease.

Glioblastoma (GBM) is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of glioblastoma cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Treatment of glioblastoma usually comprises surgical removal of the tumor followed by radiation treatment and chemotherapy using the drug temozolomide (TMZ). These treatments usually fail, mainly due to the presence of a cell subpopulation called glioma stem cells (GSCs), which are resistant to radiation and chemotherapy and capable of self-renewal and tumor generation.

As part of a program to develop methods for predicting the progression of GBM, investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) sought to determine the prognostic impact of plasma cfDNA as well as its role as a surrogate measure of tumor burden and as the subject for next-generation sequencing (NGS).

For this study, the investigators evaluated 42 patients with newly diagnosed GBM. Plasma cfDNA was quantified at baseline prior to initial tumor resection and longitudinally during chemoradiotherapy. Plasma cfDNA was assessed for its association with progression-free survival (PFS) and overall survival (OS), correlated with radiographic tumor burden, and subjected to a targeted NGS panel.

Results revealed that prior to initial surgery, GBM patients had higher plasma cfDNA concentrations than age-matched healthy controls. Plasma cfDNA concentration was correlated with radiographic tumor burden on patients' first post-radiation magnetic resonance imaging scan and tended to rise prior to or concurrently with radiographic tumor progression. Preoperative plasma cfDNA concentration above the mean was associated with inferior PFS. Thus the 28 patients with lowest pre-surgery concentrations of cfDNA - defined as cfDNA that was below the average of the total group - had almost double the length of progression free survival (median 9.5 months) compared with the 14 patients with highest concentrations (median 4.9 months).

Analysis of cfDNA samples from 20 patients by liquid biopsy detected at least one mutation in 11 patients, and all of those mutations differed from those detected in analysis of each patient's solid tumor biopsy.

"Doctors have begun using liquid biopsies more frequently to monitor certain cancers - particularly lung cancer - in recent years as research has shown their effectiveness in other disease sites. But until now, there has been little focus on the clinical utility of liquid biopsy in brain tumors," said senior author Dr. Erica L. Carpenter, assistant professor of medicine at the University of Pennsylvania School of Medicine.

The study was published in the October 30, 2019, online edition of the journal Clinical Cancer Research.

Related Links:
University of Pennsylvania School of Medicine

Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA
New
Quantitative Immunoassay Analyzer
AS050

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.